News and reports from Europe.
At Birmingham Business School we deliver world-class research and teaching that provides the insight, ambition and skills to shape advanced and sustainable business strategies. The School’s vision is to promote curiosity and thought leadership for responsible business. Birmingham Business School, along with just a handful of the world’s business schools, holds the gold standard of […]
Continue ReadingAcute kidney injury (AKI) is a common complication after cardiac surgery. The severity fluctuates from subclinical AKI, an increase in biochemical markers of kidney injury, to severe AKI requiring renal replacement therapy with dialysis. Furthermore, AKI impacts hospitalization and mortality. AKI is often diagnosed late – therefore the search for reliable biomarkers for its prediction is […]
Continue ReadingEpidemiological and clinical research and public policy in Europe are generally considered to be comprehensive and successful – and the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) is playing a key role in the field of nephrology research. But, of course, there is room for improvement. Therefore, the Nephrology and Public Policy Committee (NPPC) […]
Continue ReadingAs chronic kidney disease (CKD) progresses, the kidneys become less able to maintain a healthy balance of acids in the body, a condition known as metabolic acidosis. To maintain healthy acid levels, people with CKD are treated with alkaline substances such as sodium bicarbonate, also commonly used to neutralize heartburn and indigestion. The UBI study, […]
Continue Reading26% of patients had been employed 6 months prior to dialysis initiation – but this dropped to 15% when dialysis treatment was initiated. This is the main result of a newly published study in CKJ. Additionally, the study showed that being made redundant increased mortality. Although no causal relationship can be drawn out of this […]
Continue ReadingIn the CARMELINA trial nearly 10% of all patients with diabetes had nephrotic-range proteinuria at baseline. This was associated with a high incidence of cardiovascular/kidney disease but this secondary disease burden could not be lowered by linagliptin. The antidiabetes drug reduced albuminuria and HbA1c in all patients, but did not affect the cardiovascular (CV) risk over 2.2 […]
Continue ReadingKidney transplantation is the treatment of choice for most people with kidney failure, as it will improve their survival while increasing their quality of life compared to remaining on dialysis. However, while a kidney transplant can restore healthy kidney function, recipients remain at increased risk of fractures, heart disease, diabetes and some cancers. Observational studies […]
Continue ReadingHistorically, the number of RCTs performed in the ESRD population has been very low compared to other medical subspecialties. Furthermore, several of the few large RCTs conducted in patients with ESRD have yielded inconclusive or negative results, dampening enthusiasm for future investment in similar trials. It is therefore important for the Nephrology community to examine […]
Continue ReadingHigh cardiovascular morbidity and mortality remain a persisting problem in patients with CKD. Many efforts have been made in subjects with normal kidney function to prevent and to reduce the progression of cardiovascular diseases. However, in most of these studies, patients with advanced CKD have been excluded. Moreover, results from the general population can be […]
Continue ReadingAlport syndrome (AS) is a hereditary type IV collagen disease that leads to progressive proteinuria, renal fibrosis, and kidney failure. At present, there is no curative treatment for AS. The only recommended therapy is RAAS (renin-angiotensin-aldosterone system) blockade. Many drugs are under study, but a specific disease-modifying therapy for AS still remains an unmet need. But […]
Continue Reading
